Even though for COVID-19 ARDS, a few partially effective immunotherapeutic options have been identified in anti-IL-6 therapy and JAK inhibitors, treatment remains a challenge for bacterial sepsis-induced ARDS. This evidence concerns the gene IL6 and bacterial infectious disease with sepsis.